On February 23, 2026 Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported its participation at the 16th World ADC London Summit, taking place in London, UK, February 23-26, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Plenary/Panel Discussion Details:

Panel Discussion: ADC Licensing, Partnering & Investment Session
Sutro Participant: Hans-Peter Gerber, Ph.D.
Date/Time: February 23, 2026, 3:00PM GMT

Panel Discussion: Evaluating the Cutting-Edge Innovation & Performance Driving ADC Differentiation & Progression Earlier Line Patient Therapies
Sutro Participant: Hans-Peter Gerber, Ph.D.
Date/Time: February 24, 2026, 7:45AM GMT

Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms
Presenter: Hans-Peter Gerber, Ph.D.
Date/Time: February 25, 2026, 9:00AM GMT
Following the event, the content from the plenary session will be made available in the Scientific Publications section of Sutro Biopharma’s website at www.sutrobio.com.

(Press release, Sutro Biopharma, FEB 23, 2026, View Source [SID1234662869])